Esteban Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esteban Martinez has a total of 797 co-authors. Here are the top co-authors by number of shared publications:
- Elisa de Lazzari
HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain
22 shared publications - Ana González-Cordón
HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
15 shared publications - Berta Torres
HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
15 shared publications - Montserrat Laguno
HIV Unit, Infectious Diseases Department, Hospital Clínic de Barcelona Barcelona Spain
12 shared publications - Iván Chivite
Department of Infectious Diseases, University of Barcelona, Hospital Clinic de Barcelona, Barcelona, Barcelona, Spain
11 shared publications Josep Mallolas
HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona , Villarroel Street 170, Barcelona 08036 , Spain
11 shared publications
Latest Publications
- 10 November 2026
- Published by Wiley in HIV Medicine
Beyond borders: Making HIV prevention and care work for people on the move
- 10 November 2026
- Published by Wiley in HIV Medicine
Beyond borders: Making HIV prevention and care work for people on the move
- 19 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
What Follows an Antibiotic Is Not Necessarily Caused by It
- 19 October 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
What Follows an Antibiotic Is Not Necessarily Caused by It
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)
Background: We evaluated the efficacy and safety of a once-daily oral two-drug regimen (2DR) combining doravirine and raltegravir in virologically suppressed people with HIV (PWH). Methods: DORAL is a multicentre, open-label, randomized phase II trial conducted in France, Italy, and Spain. Virologically suppressed adults receiving stable antiretroviral therapy (ART), naïve to doravirine and without raltegravir resistance, were randomized (2:1) either to switch immediately to doravirine (100 mg) plus raltegravir (1200 mg) or to continue baseline ART until week 48 before switching to doravirine plus raltegravir. The primary endpoint was virological failure (VF; confirmed plasma HIV-1-RNA ≥50 copies/mL) at week 48. Secondary endpoints included maintenance of virological suppression through W96, immunological outcomes, safety, and pharmacokinetics in a genital sub-study. Results: Among 114 participants (median age, 57 years; median CD4 count, 700 cells/mm3; median duration of virological suppression, 10 years), one VF occurred by week 48 in the immediate-switch group (1.3%; 95% CI, 0.0–6.9); none occurred in the delayed-switch group. No additional VF was observed through week 96. Immunological parameters remained stable during follow-up. Three adverse events considered related to doravirine and raltegravir led to treatment discontinuation. One grade 3 adverse event (anxiety), considered related to study treatment, was reported. In the genital sub-study, drug concentrations exceeded inhibitory thresholds in most samples, with infrequent detection of low-level seminal HIV-1-RNA. Conclusions: This proof-of-concept phase II switch trial supports the feasibility of a once-daily doravirine plus raltegravir 2DR in selected PWH, particularly when minimizing drug-drug interactions or avoiding NRTI exposure is a priority.
- 6 October 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (11)
Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)
Background: We evaluated the efficacy and safety of a once-daily oral two-drug regimen (2DR) combining doravirine and raltegravir in virologically suppressed people with HIV (PWH). Methods: DORAL is a multicentre, open-label, randomized phase II trial conducted in France, Italy, and Spain. Virologically suppressed adults receiving stable antiretroviral therapy (ART), naïve to doravirine and without raltegravir resistance, were randomized (2:1) either to switch immediately to doravirine (100 mg) plus raltegravir (1200 mg) or to continue baseline ART until week 48 before switching to doravirine plus raltegravir. The primary endpoint was virological failure (VF; confirmed plasma HIV-1-RNA ≥50 copies/mL) at week 48. Secondary endpoints included maintenance of virological suppression through W96, immunological outcomes, safety, and pharmacokinetics in a genital sub-study. Results: Among 114 participants (median age, 57 years; median CD4 count, 700 cells/mm3; median duration of virological suppression, 10 years), one VF occurred by week 48 in the immediate-switch group (1.3%; 95% CI, 0.0–6.9); none occurred in the delayed-switch group. No additional VF was observed through week 96. Immunological parameters remained stable during follow-up. Three adverse events considered related to doravirine and raltegravir led to treatment discontinuation. One grade 3 adverse event (anxiety), considered related to study treatment, was reported. In the genital sub-study, drug concentrations exceeded inhibitory thresholds in most samples, with infrequent detection of low-level seminal HIV-1-RNA. Conclusions: This proof-of-concept phase II switch trial supports the feasibility of a once-daily doravirine plus raltegravir 2DR in selected PWH, particularly when minimizing drug-drug interactions or avoiding NRTI exposure is a priority.
- Open Access
- 11 September 2026
- Published by Wiley in HIV Medicine
Venezuelan migrants living with HIV in Barcelona : Migration patterns and baseline immunovirological characteristics in a retrospective cohort study
Objectives: To describe the sociodemographic characteristics, migration patterns and immunovirological outcomes of Venezuelan migrants living with HIV (PLWH) in Barcelona, Spain, and to compare them with other Latin American (LA) migrant PLWH. Methods: We conducted a retrospective observational cohort study including LA migrant PLWH who attended their first consultation at the HIV Unit of Hospital Clínic de Barcelona between 2000 and 2023. Venezuelan PLWH were compared with other LA migrant PLWH regarding demographics, HIV diagnosis timing, CD4 cell count, viral load, late HIV diagnosis (LHD) and advanced HIV disease (AHD). Results: A total of 493 Venezuelan PLWH were included, representing 16% of LA migrant PLWH in the cohort. Venezuelan PLWH were predominantly men (97%; n = 478). Most first consultations occurred after 2014 (81%; n = 399), peaking in 2018. Half were diagnosed with HIV after arrival in Spain (50%; 224/451), and 73% (328/451) had lived in Spain for less than 3 years. Among ART‐naïve individuals, LHD was 38% in 2000–2008 and 53% in 2015–2023, while baseline CD4 counts progressively declined. Immunological outcomes were similar between Venezuelan and other LA migrants, including LHD (50%; n = 98 vs. 51%; n = 622) and AHD (24%; n = 48 vs. 25%; n = 301). However, ART‐experienced Venezuelan PLWH showed lower virological suppression rates (67%; n = 191 vs. 72%; n = 1013; p = 0.068). Conclusion: Venezuelan PLWH in this Barcelona cohort represent a rapidly growing migrant population shaped by humanitarian displacement and disruption of HIV care. The high proportion of LHD and lower virological suppression among ART‐experienced individuals is compatible with continuity‐of‐care disruptions before migration but do not establish causality.
- 11 September 2026
- Published by Wiley in HIV Medicine
Open AccessVenezuelan migrants living with HIV in Barcelona : Migration patterns and baseline immunovirological characteristics in a retrospective cohort study
Objectives: To describe the sociodemographic characteristics, migration patterns and immunovirological outcomes of Venezuelan migrants living with HIV (PLWH) in Barcelona, Spain, and to compare them with other Latin American (LA) migrant PLWH. Methods: We conducted a retrospective observational cohort study including LA migrant PLWH who attended their first consultation at the HIV Unit of Hospital Clínic de Barcelona between 2000 and 2023. Venezuelan PLWH were compared with other LA migrant PLWH regarding demographics, HIV diagnosis timing, CD4 cell count, viral load, late HIV diagnosis (LHD) and advanced HIV disease (AHD). Results: A total of 493 Venezuelan PLWH were included, representing 16% of LA migrant PLWH in the cohort. Venezuelan PLWH were predominantly men (97%; n = 478). Most first consultations occurred after 2014 (81%; n = 399), peaking in 2018. Half were diagnosed with HIV after arrival in Spain (50%; 224/451), and 73% (328/451) had lived in Spain for less than 3 years. Among ART‐naïve individuals, LHD was 38% in 2000–2008 and 53% in 2015–2023, while baseline CD4 counts progressively declined. Immunological outcomes were similar between Venezuelan and other LA migrants, including LHD (50%; n = 98 vs. 51%; n = 622) and AHD (24%; n = 48 vs. 25%; n = 301). However, ART‐experienced Venezuelan PLWH showed lower virological suppression rates (67%; n = 191 vs. 72%; n = 1013; p = 0.068). Conclusion: Venezuelan PLWH in this Barcelona cohort represent a rapidly growing migrant population shaped by humanitarian displacement and disruption of HIV care. The high proportion of LHD and lower virological suppression among ART‐experienced individuals is compatible with continuity‐of‐care disruptions before migration but do not establish causality.
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study
Objectives: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). Methods: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. Results: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. Conclusions: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.
- 1 September 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (10)
Switching from etravirine to doravirine in people with HIV harbouring NNRTI resistance-associated mutations: the DorSwitch pilot study
Objectives: The objective of this study is to evaluate the efficacy, resistance profile, pharmacokinetics (PK) and safety of switching from etravirine to doravirine in virologically suppressed, treatment-experienced individuals with prior non-nucleoside reverse transcriptase inhibitor (NNRTI)-associated resistance mutations (NNRTI-RAMs). Methods: DorSwitch is a prospective pilot study including 13 adults with sustained virological suppression and documented historical NNRTI-RAMs. Etravirine was replaced by doravirine while maintaining the remaining antiretroviral backbone. Drug-specific resistance penalty scores were generated using the Stanford HIV Drug Resistance Database (HIVdb) algorithm. PK analyses were performed in participants receiving darunavir/cobicistat plus doravirine. Virological, immunological, metabolic and safety outcomes were assessed over 48 weeks. Results: Twelve participants completed 48 weeks of follow-up; one discontinued at Week 4 for personal reasons while virologically suppressed. All participants evaluable at Weeks 24 and 48 maintained HIV-1 RNA < 50 copies/mL, and no virological failures occurred. The median number of NNRTI-RAMs per individual was 2 (IQR 1–3). Doravirine showed lower or equal Stanford HIVdb penalty score (HIVdb-PS) than etravirine in 11/13 participants. In two cases, higher doravirine PS were driven by Y318F and G190E mutations detected in peripheral blood mononuclear cell HIV-1 DNA; both individuals remained virologically suppressed through Week 48. In seven participants receiving darunavir/cobicistat plus doravirine, trough concentrations (Cmin) were consistent with expected exposure concentrations. Total cholesterol and LDL cholesterol decreased significantly over follow-up, while body weight showed a modest, non-significant reduction. No doravirine-related serious adverse events were observed. Conclusions: In this small, highly selected pilot cohort, switching from etravirine to doravirine as part of an otherwise suppressive regimen was associated with maintenance of virological suppression through Week 48 and a more favourable predicted NNRTI resistance profile in most participants. The favourable resistance profile, safety, metabolic effects and PK findings consistent with expected exposure—particularly in combination with darunavir/cobicistat— support further evaluation of doravirine as a switch option in carefully selected individuals with prior NNRTI failure.
- Open Access
- 23 August 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 99, 104158
Reduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain
- 23 August 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 99, 104158
Open AccessReduced-frequency bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV: a single-centre randomised phase 2 pilot trial in Spain
- Open Access
- 19 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Annual vs Semi-Annual Follow-up in Low-Complexity, Virologically Suppressed People With HIV: A Randomized Interventional Trial
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.
- 19 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessAnnual vs Semi-Annual Follow-up in Low-Complexity, Virologically Suppressed People With HIV: A Randomized Interventional Trial
Background: Increasing heterogeneity among people with HIV requires evaluation of new follow-up strategies tailored to clinical/social complexity. Methods: Prospective, single-center, randomized, noninferiority trial comparing semi-annual standard of care (SoC) with annual follow-upover 24 months in virologically suppressed people with HIV with low-complexity profile according to the GeSIDA HIV Patient Stratification System. The primary endpoint was noninferiority (prespecified lower margin: −4%) in virological control (viral load <50 copies/mL; FDA snapshot). Secondary outcomes included adherence, quality of life, satisfaction, and healthcare costs. Results: Of 394 eligible candidates, 71 declined participation (48% preferred SoC) and 321 were randomized (162 SoC, 159 Annual). Participants were predominantly male (89%), men who have sex with men (78%), Spanish (63%), with a median age of 45 years and 13 years of HIV follow-up, without baseline differences between groups. Overall, 283 (88%) completed the study; 25 switched to long-acting therapy and 10 were lost or transferred. Virological control was similar in SoC and annual arms: 86.42% vs 86.79% (intention to treat) and 98.29% vs 97.87% (per protocol), although noninferiority was not statistically demonstrated. The proportion of highly satisfied participants increased significantly from baseline to 24 months in the annual arm (P = .001). Reductions in HIV-related direct costs (−25.3%; P < .001) were greater in the Annual group. Conclusions: Among people with HIV and low complexity, annual follow-up achieved virological outcomes clinically comparable to semi-annual care, despite not meeting the formal noninferiority threshold. Annual follow-up was associated with a significant increment in patient satisfaction and lower HIV-related direct costs.
- Open Access
- 9 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1752
Community-Associated Methicillin-Resistant Staphylococcus aureus Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV Who Engage in Chemsex in Barcelona, Spain: Epidemiological Patterns and Implications for Infection Control
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly reported among gay, bisexual, and other men who have sex with men (GBMSM) engaging in chemsex, yet data remain limited. This ambispective cohort study conducted at Hospital Clínic of Barcelona (2018–2024) aimed to characterize CA-MRSA infections among GBMSM living with HIV. Methods: Epidemiological, behavioral, and clinical data were collected from medical records and standardized questionnaires. MRSA isolates from clinically indicated samples were identified by mass spectrometry and underwent antimicrobial susceptibility testing. Results: Among 446 participants, 62 (14%) were diagnosed with CA-MRSA, accounting for 109 infection episodes over a median follow-up of 3.21 years (IQR 1.39–5.05). All episodes involved skin and soft-tissue infections; 17% required hospitalization, 35% surgery, and 51% received non-active empirical antibiotics. Recurrent infections occurred in 32% of participants, and detectable HIV viral load was present in 28% of episodes. High levels of polydrug use were reported. Resistance to clindamycin (33%), cotrimoxazole (23%), and mupirocin (96%) was observed. Decolonization was attempted in 65% of participants. Conclusions: CA-MRSA infections were frequent, with substantial recurrence and antimicrobial resistance. These findings highlight challenges for infection control and antimicrobial stewardship and support further evaluation of preventive and decolonization strategies in this population.
- 9 August 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (8) , 1752
Open AccessCommunity-Associated Methicillin-Resistant Staphylococcus aureus Among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV Who Engage in Chemsex in Barcelona, Spain: Epidemiological Patterns and Implications for Infection Control
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasingly reported among gay, bisexual, and other men who have sex with men (GBMSM) engaging in chemsex, yet data remain limited. This ambispective cohort study conducted at Hospital Clínic of Barcelona (2018–2024) aimed to characterize CA-MRSA infections among GBMSM living with HIV. Methods: Epidemiological, behavioral, and clinical data were collected from medical records and standardized questionnaires. MRSA isolates from clinically indicated samples were identified by mass spectrometry and underwent antimicrobial susceptibility testing. Results: Among 446 participants, 62 (14%) were diagnosed with CA-MRSA, accounting for 109 infection episodes over a median follow-up of 3.21 years (IQR 1.39–5.05). All episodes involved skin and soft-tissue infections; 17% required hospitalization, 35% surgery, and 51% received non-active empirical antibiotics. Recurrent infections occurred in 32% of participants, and detectable HIV viral load was present in 28% of episodes. High levels of polydrug use were reported. Resistance to clindamycin (33%), cotrimoxazole (23%), and mupirocin (96%) was observed. Decolonization was attempted in 65% of participants. Conclusions: CA-MRSA infections were frequent, with substantial recurrence and antimicrobial resistance. These findings highlight challenges for infection control and antimicrobial stewardship and support further evaluation of preventive and decolonization strategies in this population.
- 5 July 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (10) , 1617-1628
Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH‐1 multicentre cohort study
Background: Clinical outcomes of mpox (clade IIb) among people living with HIV (PWH) require clarification, particularly the role of immune status in determining disease severity. This multicentre study assessed differences in mpox clinical outcomes and hospitalization between PWH and PrEP users across European clinical settings. Methods: Individuals with PCR‐confirmed mpox attending sexual health/HIV and infectious diseases services in 11 European countries between May 2022–December 2023 were included. Comparisons between PWH versus PrEP users were made using Chi‐square tests for categorical variables and t ‐tests for continuous variables; adjusted analyses accounting for study site used mixed‐effects logistic and Cox regression models. Univariable and multivariable models assessed key predictors. Results: The proportion of clinic attendees with mpox ranged from 0.34%–3.07% across sites (946 PWH, 1054 PrEP users). Overall, 745/1989 (37%) individuals experienced at least one mpox‐related clinical complication. Median time to lesion resolution was 18 days (IQR 13–23). No deaths occurred. In unadjusted analysis, hospitalization was more frequent among PWH (57/946, 6% vs. 38/1054, 4%; p = 0.011), but this difference was not significant after site‐adjustment ( p = 0.389). Despite low numbers, among PWH with recent CD4 measurements, CD4 < 200/mm 3 was associated with significantly increased hospitalization (36% vs. 4%; p = 0.003). Immunosuppression was linked to hospitalization (aOR 3.00, 95% CI 1.03–8.78). Conclusions: Mpox clinical outcomes were generally favourable in both PWH and PrEP users with adequate immune function. Severe immunosuppression, rather than HIV status per se, was associated with hospitalization risk. These findings support prioritized clinical monitoring for individuals with advanced immunodeficiency and highlight the importance of immune status assessment in mpox management.
- 5 July 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (10) , 1617-1628
Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH‐1 multicentre cohort study
Background: Clinical outcomes of mpox (clade IIb) among people living with HIV (PWH) require clarification, particularly the role of immune status in determining disease severity. This multicentre study assessed differences in mpox clinical outcomes and hospitalization between PWH and PrEP users across European clinical settings. Methods: Individuals with PCR‐confirmed mpox attending sexual health/HIV and infectious diseases services in 11 European countries between May 2022–December 2023 were included. Comparisons between PWH versus PrEP users were made using Chi‐square tests for categorical variables and t ‐tests for continuous variables; adjusted analyses accounting for study site used mixed‐effects logistic and Cox regression models. Univariable and multivariable models assessed key predictors. Results: The proportion of clinic attendees with mpox ranged from 0.34%–3.07% across sites (946 PWH, 1054 PrEP users). Overall, 745/1989 (37%) individuals experienced at least one mpox‐related clinical complication. Median time to lesion resolution was 18 days (IQR 13–23). No deaths occurred. In unadjusted analysis, hospitalization was more frequent among PWH (57/946, 6% vs. 38/1054, 4%; p = 0.011), but this difference was not significant after site‐adjustment ( p = 0.389). Despite low numbers, among PWH with recent CD4 measurements, CD4 < 200/mm 3 was associated with significantly increased hospitalization (36% vs. 4%; p = 0.003). Immunosuppression was linked to hospitalization (aOR 3.00, 95% CI 1.03–8.78). Conclusions: Mpox clinical outcomes were generally favourable in both PWH and PrEP users with adequate immune function. Severe immunosuppression, rather than HIV status per se, was associated with hospitalization risk. These findings support prioritized clinical monitoring for individuals with advanced immunodeficiency and highlight the importance of immune status assessment in mpox management.
- Open Access
- 18 June 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (9) , 1537-1547
Awareness and early implementation of the European AIDS Clinical Society Guidance on statin use in HIV for the primary prevention of cardiovascular disease: A cross‐sectional survey of HIV clinicians in Europe
Objectives: Cardiovascular disease (CVD) is a major comorbidity and leading cause of morbidity and mortality in people with HIV (PWH). The REPRIEVE trial demonstrated that statin therapy significantly reduces cardiovascular events in PWH, prompting updated recommendations from major international societies. We assessed awareness and early implementation of the European AIDS Clinical Society (EACS) statin guidance among HIV clinicians in Europe. Materials and Methods: We conducted an anonymous cross‐sectional online survey among members of the EACS Young Investigators Network Group (YING). The questionnaire evaluated clinician characteristics, reported awareness and implementation of statin guidance, cardiovascular risk assessment practices, prescribing patterns and perceived barriers. Descriptive analyses were performed. Results: Of 125 individuals invited to take part in the survey, 22 (18%) physicians from multiple European countries responded. All respondents were aware of the EACS statin guidance, and 91% reported that it influenced clinical practice. Cardiovascular risk was routinely assessed by most clinicians (77% always or often), with HIV physicians primarily responsible for statin prescribing (59%). Structural barriers reported included reimbursement limitations, fragmented care pathways and patient‐level barriers, such as low perceived CVD risk and statin hesitancy. Conclusions: Awareness of EACS statin guidance among this cohort of HIV clinicians in Europe who are YING members is reported as high, but implementation gaps remain. Addressing structural and patient‐level barriers and improving guideline implementation will be essential to optimize CVD prevention in PWH.
- 18 June 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (9) , 1537-1547
Open AccessAwareness and early implementation of the European AIDS Clinical Society Guidance on statin use in HIV for the primary prevention of cardiovascular disease: A cross‐sectional survey of HIV clinicians in Europe
Objectives: Cardiovascular disease (CVD) is a major comorbidity and leading cause of morbidity and mortality in people with HIV (PWH). The REPRIEVE trial demonstrated that statin therapy significantly reduces cardiovascular events in PWH, prompting updated recommendations from major international societies. We assessed awareness and early implementation of the European AIDS Clinical Society (EACS) statin guidance among HIV clinicians in Europe. Materials and Methods: We conducted an anonymous cross‐sectional online survey among members of the EACS Young Investigators Network Group (YING). The questionnaire evaluated clinician characteristics, reported awareness and implementation of statin guidance, cardiovascular risk assessment practices, prescribing patterns and perceived barriers. Descriptive analyses were performed. Results: Of 125 individuals invited to take part in the survey, 22 (18%) physicians from multiple European countries responded. All respondents were aware of the EACS statin guidance, and 91% reported that it influenced clinical practice. Cardiovascular risk was routinely assessed by most clinicians (77% always or often), with HIV physicians primarily responsible for statin prescribing (59%). Structural barriers reported included reimbursement limitations, fragmented care pathways and patient‐level barriers, such as low perceived CVD risk and statin hesitancy. Conclusions: Awareness of EACS statin guidance among this cohort of HIV clinicians in Europe who are YING members is reported as high, but implementation gaps remain. Addressing structural and patient‐level barriers and improving guideline implementation will be essential to optimize CVD prevention in PWH.